Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 14/20 | 0.41 |
| ▸ | CA2 | P00918 | 14/20 | 0.41 |
| ▸ | CA9 | Q16790 | 13/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787646 | 0.84 | PIK3CD (0.43) | KMT2ACA1CA2CA9CA12 | |
| SCHEMBL2787648 | 0.84 | PIK3CD (0.43) | KMT2ACA1CA2CA9CA12 | |
| SCHEMBL4775747 | 0.81 | GPR84 (0.38) | KMT2A | |
| SCHEMBL4765880 | 0.79 | ROCK1 (0.43) | KMT2ACA1CA2CA9CA4 | |
| SCHEMBL5225461 | 0.75 | PIK3CD (0.43) | — | |
| SCHEMBL4774422 | 0.75 | CYP2C9 (0.36) | KMT2A | |
| SCHEMBL4872082 | 0.72 | MAPT (0.46) | KMT2A | |
| SCHEMBL4770645 | 0.72 | NEK2 (0.39) | — | |
| SCHEMBL4867386 | 0.70 | PIK3CD (0.47) | KMT2A | |
| SCHEMBL4776074 | 0.69 | NPC1 (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | claimed |